Metabolic disturbances as insulin resistance, dyslipidemia, and hyperglycemia are closely related to elevated ALT; a cut-off point of AST/ALT ratio <1 has been defined for hepatic steatosis assessment in obese patients [12]. This evidence concerns the gene GPT and fatty liver disease.